Overview
Experience has shown that the development of new antiviral drugs requires a decades-long effort by multidisciplinary teams in academia, government and the pharmaceutical industry. To help prepare the next generation of researchers to take part in this process, a summer school, focusing on innovative approaches for the identification of antiviral agents (IAAASS), was organized for the first time in September, 2012 by researchers of the Universities of Cagliari and Padova, Italy, and the National Cancer Institute, USA.
The IAAASS aimed to bring together scientists early in their careers with internationally recognized experts to encourage the sharing of knowledge and experience in virology research and drug development in an informal and interactive environment.
The success of the first summer school led to a second, similar conference in September, 2014. In turn, the third IAAASS was held from September 28th to October 2nd, 2016 at the Sardegna Ricerche Research Park in Santa Margherita di Pula, Sardinia, Italy. Like the first two meetings, the third IAAASS brought together graduate students, postdoctoral researchers and senior investigators for five days of presentations and discussion. In the mornings, participants attended plenary lectures from leading scientists in the fields of virology, biochemistry, molecular modeling, crystallography and medicinal chemistry, while afternoon sessions were devoted to oral presentations from students and postdocs. In the evenings, all participants met in small, informal groups, in which students had the opportunity to ask questions and put forward their own ideas, and in return senior researchers offered advice, based on their own experience.
This report summarizes presentations and discussions at the third IAAASS. The following text is divided into five sections. The first summarizes the organization and financial support for the conference. The second contains brief summaries of plenary lectures by senior researchers. The third provides an account of discussions among faculty and students, on topics including the relative advantages of working in academia, government or industry; problems encountered in the course of research; choosing a thesis topic; new approaches in drug development; and advice for publishing scientific reports. The fourth section contains highlights of an interactive round-table discussion of career paths, while the fifth summarizes student evaluations of the meeting. The conclusion examines lessons learned during the third IAAASS that might be applied in planning future conferences. A supplementary file provides the abstracts of short oral presentations and posters by students and postdocs.
Organization, financial support and application procedure
The organizing committee consisted of Enzo Tramontano and Elias Maccioni, University of Cagliari, Italy; Cristina Parolin, University of Padua, Italy; Stuart Le Grice, National Cancer Institute, Frederick, MD, USA; and Katarzyna Purzycka, Polish Academy of Sciences, Poznan, Poland. Lecture sessions were held at the Sardegna Ricerche Research Park in Pula, Sardinia, Italy. Sardegna Ricerche, established in 1985, is the Sardinian Agency for R&TD whose primary mission is to promote research and technology transfer and the development of a knowledge-based local economy.
Eighteen senior scientists and 48 graduate students and postdoctoral fellows attended the third IAAASS. Students and fellows submitted an application and an abstract describing a current research project to the IAAASS secretariat. The organizing committee selected participants based on the abstracts, choosing some to give short oral presentations and the remainder to present their data in the form of a poster. Financial support was provided by Sardegna Ricerche, while the European Society for Virology, the Federation of European Microbiological Societies, the International Antiviral Symposium Foundation and Fondazione di Sardegna provided travel grants and support for student accommodation.
Plenary lectures
Senior faculty were invited to participate in the IAAASS based on their recognized scientific stature and their experience in research in academic and governmental settings and/or the pharmaceutical industry. In their lectures, the faculty shared both their knowledge of virology, medicinal chemistry and drug development and their personal experience in performing successful research. The presentations covered topics in four general areas: epidemiology and pathogenesis of viral diseases; development of new direct-acting antivirals; drug delivery and the development of viral drug resistance; and antiviral strategies targeting host cell mechanisms.
Epidemiology and pathogenesis of viral diseases
Mike Bray, editor-in-chief of Antiviral Research, reviewed the wide variety of viruses that are maintained through circulation in animals, but can cause disease in humans. He observed that approved antiviral therapies are now available for a number of chronic viral infections, such as hepatitis C, but despite several decades of research, therapeutic countermeasures against viral zoonoses remain limited. Although it is often straightforward to demonstrate the activity of an antiviral drug against a zoonotic virus in cell culture and in laboratory animals, delivering novel therapies to patients and demonstration of efficacy in field settings present many challenges. He concluded that broad-spectrum antivirals such as favipiravir represent the best available therapy for many viral zoonoses, at least for the near future.
Giorgio Palù, University of Padova, Italy and President of the European Society of Virology, provided an overview of current research on Zika virus. The recent unexpected emergence of Zika virus in the Western Hemisphere and its association with GuillainBarr e syndrome and with microcephaly in infants of women infected during pregnancy has led to intense efforts to understand its pathogenesis and develop effective countermeasures. The persistence of virus in the semen of male patients is of particular concern, calling for new strategies to prevent sexual transmission. New mouse models of Zika virus infection appear to recapitulate some of the mechanisms of transplacental transmission and spread to the fetal nervous system. Anna Papa of Aristotle University, Thessaloniki, Greece reviewed emerging viral infections in the Mediterranean region, most of which are transmitted by the bite of mosquitoes or ticks. Among the former, West Nile virus has caused large outbreaks, with different lineages responsible for disease in Balkan countries and in Turkey and Israel. Zika virus remains limited to imported cases, though the capacity for autochthonous spread is present. Among tick-borne diseases, Crimean-Congo hemorrhagic fever is the most important, but the least understood, as shown by its recent unexpected emergence in Spain, far to the west of any previously recognized cases. Tick-borne encephalitis also appears to be expanding its range in southern Europe.
Development of new direct-acting antivirals
Robert Jordan, Gilead Sciences, Foster City, CA, USA, presented the development history of a new orally available inhibitor of respiratory syncytial virus (RSV), which began with screening of over 500,000 compounds. Hits of different chemical classes were then ranked by their antiviral activity and drug-like properties, and the most promising underwent further modification to increase their potency and to enhance oral absorption and delivery to the lungs. This systematic approach led to the identification of GS-5806 (Presatovir ® ), which inhibits RSV replication with an EC 50 of <1 nM by inhibiting F-protein-mediated fusion of the viral envelope with the cell membrane. Presatovir has good oral bioavailability and minimal toxicity; it was protective against RSV challenge in cotton rats and calves and in a study in human volunteers. It is now in Phase II clinical trials. Vincenzo Summa, IRBM Science Park in Pomezia, Italy, chronicled the discovery and development of raltegravir (Isentress ® ), the first-in-class HIV integrase inhibitor. The story began with efforts to develop new drugs targeting the hepatitis C RNA polymerase, and the observation that some compounds were active in assays measuring HIV integration. Further development included the synthesis and evaluation of multiple chemical variants, which were evaluated for protein binding in human serum and cell permeability. Pharmacokinetic and metabolic profiles completed the chemical biography. Success in developing this new antiviral demonstrates the value of an interdisciplinary approach and creative medicinal chemistry.
Stuart Le Grice of the US National Cancer Institute (NCI), Frederick, MD, USA described the repurposing of some natural product molecules, which were initially evaluated as inhibitors of the Ribonuclease H (RNase H) activity of the HIV-1 reverse transcriptase. The mechanism of action of manicol and other related ahydroxytropolones was found to involve sequestration of a divalent metal ion at the active site of RNase H. When they failed to advance to clinical use, the compounds were screened against other viruses, and proved to be active against herpes simplex viruses type 1 and 2 (HSV-1, HSV-2), based on the structural similarity between the HIV RNase H and the HSV terminase component pUL15, whose C-terminal nuclease domain employs a 2-metal ion-mediated catalytic mechanism to cleave concatameric viral DNA. Screening was facilitated by the replacement of a traditional assay employing supercoiled DNA with a simpler system, based on cleavage of short oligonucleotide duplexes containing a fluorescence donor/ quencher pair.
María-Jos e Camarasa, Instituto de Química M edica, Madrid, Spain, described efforts to develop new therapies for a range of viral diseases. Focusing on chikungunya fever, her group identified a set of compounds that target the NSP1-mediated capping of viral mRNA. Recognizing the need for countermeasures against enteroviruses, especially EV71, they applied their experience with tryptophan dendrimers as anti-HIV agents, and developed a consensus molecule that suppresses EV71 replication at sub-nanomolar concentrations. She also described novel acyclic nucleoside phosphonates incorporating 2,4-diaminotriazine, which have potent activity against HIV and hepatitis B virus.
Stefano Alcaro, Magna Graecia University, Catanzaro, Italy, discussed new computational tools for the development of multitargeting bioactive agents. He noted that the traditional paradigm of "one target, one drug" has recently been reformulated to include compounds that act on more than one target simultaneously, as demonstrated by the repurposing of compounds originally developed for other diseases. While promising, this approach complicates drug discovery by requiring assessment of multi-target drug profiles. This effort is supported by a new initiative of European Cooperation in Science and Technology (COST), the Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig), which began through a joint effort of five research teams and will continue through 2020.
Katarzyna Purzycka, Polish Academy of Sciences, Poznan, Poland, described the expanding field of structural studies of retroviral RNAs, which may offer new targets for direct-acting antivirals. The ability of RNA strands to form stable tertiary structures that interact with host proteins is fundamental to their function. In particular, the genomic RNA of retroviruses and related retrotransposons serves as a template for translation, but also takes on structures that are required for dimerization, nucleocytoplasmic transport, priming of reverse transcription and packaging into virions. She noted that, while advances in probing methods and prediction algorithms now facilitate modeling of RNA secondary structure, the determination of tertiary structure remains a significant challenge.
Drug delivery and development of drug resistance
Joel Schneider, NCI, Frederick, MD, USA noted that many promising antiviral compounds have failed to advance to clinical use because of low cell permeability. He then reviewed the basic properties of polypeptide gels, and showed how their reduced viscosity under pressure might permit delivery of therapeutics into tissues by injection. He next described the design of peptides that can deliver membrane-impermeable compounds directly to the cell cytoplasm. While earlier molecules became trapped in endosomes or caused unacceptable levels of cell lysis, the novel peptide CLIP6 is intrinsically disordered and can transport a drug cargo to the cytoplasm without disrupting the cell membrane. This strategy has direct applications to the treatment of solid tumors and the delivery of antivirals.
Graciela Andrei, Rega Institute, Leuven, Belgium, presented data collected since 2009 by a reference center (Regavir) for the detection and characterization of drug-resistant herpesviruses recovered from immunocompromised patients. After reviewing the basic biology of human disease caused by a, b-and g-herpesviruses and current antiviral therapies, she described the genomic locations of drug-resistance mutations found in clinical samples. Mutations in HCMV localize principally to the UL97 protein kinase and the DNA polymerase; for herpes simplex and varicella zoster viruses, to the thymidine kinase and DNA polymerase; and for human herpesvirus 6, to the U69 protein kinase and DNA polymerase. The Regavir database has expanded understanding of drug resistance and shown the value of genotyping for the rapid adjustment of antiviral therapy.
Antiviral strategies targeting host-cell mechanisms
Maurizio Botta, University of Siena, Italy, reviewed the role of the cellular helicase DEAD-box 3 (DDX3) as an essential host factor for the replication of HIV, hepatitis C and other viruses. Direct-acting antivirals may be handicapped by the evolution of drug resistance, but interventions directed at cellular mechanisms should not have this limitation. Following this approach, his research group has found that compounds that block the DDX3 helicase inhibit the replication of HIV, HCV, dengue, West Nile and Japanese encephalitis viruses at submicromolar concentrations.
Jos e Est e, Autonomous University of Barcelona, Spain and President of the International Society of Antiviral Research, began his lecture by reviewing the role of cellular sensing mechanisms in resistance to viruses, and pointed out that the restriction of viral replication in monocytes and myeloid cells represents the first line of defense against infection. His group has been focusing on the restriction of HIV replication in primary macrophages and the link between restriction and control of the cell cycle, cellular proliferation and activation of type I interferon responses. Elucidation of pathways of recognition of foreign DNA or RNA may lead to new means of antiviral defense, and has particular application to attempts to eradicate latently infected cells.
Reuben Harris, University of Minnesota, USA, reviewed the APOBEC family of cytosine deaminases. During HIV infection, APOBEC3G is carried within virions to the next infected cell and becomes active during uncoating, inducing multiple mutations in the viral genome. Vif, which is encoded by HIV, binds to APOBEC3G and initiates its degradation through ubiquitination. These observations suggest an antiviral strategy, based on the induction of hypermutation by inhibiting Vif. A complementary strategy might also facilitate efforts to eradicate HIV, by slowing the rate of mutation. APOBEC3 enzymes also play a role in cancer, as higher levels result in faster tumor cell mutation, and knockdown of A3B enhances the activity of tamoxifen.
Thomas Mertens, Ulm University, Germany, reminded participants that prevention of viral disease through elicitation of protective immune responses is more desirable than treatment. He presented several alternative strategies for augmenting virusspecific immunity in immunocompromised patients chronically infected with cytomegalovirus. NK cells play an important role in protection, but require anti-HCMV antibodies to kill infected macrophages. Transfer of virus-specific T cells from seropositive donors can prevent or treat infection after hematopoietic stem cell transplantation. He presented experimental evidence that therapeutic vaccination may be beneficial for HSCT recipients, as most patients who received a series of peptide inoculations cleared their HCMV infection.
Round-table discussion of career choices
A unique feature of the IAAASS was a discussion among the student participants and a panel of senior investigators on the advantages or disadvantages of pursuing an academic career, as opposed to joining a pharmaceutical company. The panel members were Robert Jordan, Director of Biology, Gilead Sciences, CA, USA, Stuart Le Grice, Senior Investigator, NCI, USA and Vincenzo Summa, Head of Chemistry, IRBM Science Park, Italy. Each panel member provided a brief account of his experience in either or both of the academic and industrial settings.
Stuart Le Grice began the discussion by relating his sequential employment as a Senior Scientist with Hoffman La-Roche, a Professor of Medicine at Case Western Reserve University and a Senior Investigator at the NCI. He challenged students who have decided to pursue an academic career to explain why they would not consider working in the pharmaceutical industry, and vice-versa. He pointed out that, regardless of the setting, modern biomedical research is multidisciplinary and team-oriented. An advantage of industry is a company's ability to rapidly assemble the necessary expertise; as a result, each team member can see the project as a whole, and can follow the drug discovery process from concept through scale-up of the final product. Harnessing the same manpower and expertise in an academic setting represents a greater challenge, and one that may not be accomplished within the necessary timeframe. The panel members agreed on these questions, as all had been directly involved in the drug development process.
While lack of freedom to publish was seen as a disadvantage of a career in the pharmaceutical industry, the discussants pointed out that many universities now encourage researchers to promptly seek patent protection for any novel discovery that could have commercial applications, which may also restrict or delay publication. Uncertain job security with a company was another issue raised by the students, who were concerned that they could become victims of business decisions beyond their control. Although the panel conceded this issue, they pointed out that, in today's highly competitive academic environment, the consequences of losing one's research funding could be equally dire.
Perhaps the most difficult question posed by the students was to explain the process of professional advancement within the pharmaceutical industry, from the laboratory bench to a senior management position. Panel members noted that promotion is often based on the ability of certain team members to take the initiative, make strategic decisions that impact a team's overall effectiveness, and accept responsibility for the success or failure of a project. In that way, such individuals demonstrate the interpersonal and communication skills that will provide leadership for the company.
Finally, the panel agreed that the personal experience of working in industry, through a short-term visit or a more extended period of postdoctoral research, is the best way to make an informed decision. When choosing an industrial career, students were advised not to "marry" a project, since it could be deprioritized without warning, resulting in a rapid "divorce". Regardless of their ultimate choice, students were reminded that the award of a doctoral degree symbolizes not only their ability to successfully perform research, but also to recognize and solve unexpected problems e a skill they can apply in many areas beyond their immediate goals.
Small-group discussions
Interaction among participants is the key aspect of a conference, as it invigorates interest by providing contact among like-minded people who share a passion for science. For researchers early in their careers, it can also be fascinating to interact directly with some of the "big names" in science. With 18 plenary speakers and 48 young investigators, the snug format of the IAAASS assured successful communication.
Morning and afternoon sessions were devoted to plenary lectures, short talks and poster viewing, and evenings centered around loosely organized discussions. Participants were divided into six groups of three faculty members and seven younger scientists. As many students may be reluctant to ask questions, either because of language barriers, or for fear of seeming rude or selfpromotional, the low-key settings were designed to avoid these issues. By looking for shared points of interest in different research fields, the discussion topics encouraged a collaborative spirit, rather than competition. The participants were the appropriate mix, including senior researchers whose informal communicative skills were powered by enthusiasm rather than self-importance, and young investigators who were eager to listen and ask questions.
The discussion themes were dictated in part by the subjects of the meeting, but were also adjusted according to the interests of each group. Scientific topics included drug targets and methods of screening, host factors, virus-host interactions and drug design. The participants talked about the main challenges they faced while optimizing cellular and biochemical assays, including problems with reproducibility of data, as well as the necessity of connecting studies performed in different sessions. Potential antiviral targets (viral proteins, RNA and DNA, or host factors) as well as therapies, e.g. natural products vs. chemical analogs, were foci for examination, as each approach has its nuances. As a hallmark of the success of these small group discussions, students were excited to talk about the implications of their work and develop professional networking connections (Research Gate, Facebook, Linkedin, WhatsApp etc.) .
Discussion groups also focused on common problems such as early-career setbacks, the difficulties young investigators must overcome when working abroad, and continuing challenges faced by women in science. The debate on the advantages and disadvantages of working in industry, academia and government continued in the discussion groups. Issues of unethical behavior and suggestions for good authorship practice were also examined, as young scientists are often unaware of the pathways they can take to solve these disputes.
Because science involves collaborative efforts among researchers in different fields, productive discussions are fundamental. The IAAASS provided an ideal arena for building relationships among participants. The daytime setting of the Sardegna Ricerche Research Park prevented distractions, while the conference hotel in the evening provided a relaxed environment that was ideal for dynamic discussions and social interactions.
At the conclusion of the summer school, all participants knew each other and eagerly exchanged their contact information to stay in touch and continue collaborative efforts. Social networking website and applications such as Facebook and Research Gate will help to maintain these relationships.
Evaluation of the 3rd IAAASS
In a questionnaire given out on the last day of the meeting, more than 80% of students and postdocs stated that the IAAASS had met their primary objectives, and nearly all said it would influence their future work. Some 40% noted that they had been attracted to the event principally by the opportunity for networking, while the remainder had chosen it because of the overall agenda and list of speakers. Two-thirds rated the relevance of presentation topics "excellent," while 50% found the group discussions "excellent" and 40% "very good."
Specific comments noted that the summer school had been very useful, with a good mix of scientific disciplines and many opportunities for collaboration; that the presence of a diverse group of international researchers provided "huge" discussion possibilities; and it showed that senior scientists "can be reached by students, and are happy to talk and exchange with them." The IAAASS achieved the criteria for successful mentoring: a combination of critical review of the scientific literature, sharing of ideas and discussion of new paradigms for research.
Recommendations for improvement and conclusion
Members of the Organizing Committee would agree that the first IAAASS was an experimental venture, but its continued appeal to an increasingly international audience indicates that it is succeeding in its overall mission of encouraging students early in their careers to continue in biomedical research. The summer school has benefitted from the willingness of leaders in the field to provide information and advice throughout the meeting, encourage questions during plenary talks, engage in one-on-one interactions during the poster sessions and allow students to take the lead in informal group discussions.
With this "recipe" in mind, a more structured contribution from student participants might be considered at future meetings.
Options under consideration include:
-Expanding the round-table discussion to include a student participant, whose own experiences and opinions might help drive the discussion; -Changing the theme of the round-table, focusing perhaps on ethical conduct in science; -Inviting students to chair or co-chair scientific sessions, as a means of promoting communication; -Soliciting general discussion themes from students as well as faculty members, perhaps by a questionnaire sent out before the meeting;
Scientific endeavor has many fundamental aspects that are key for success. Among the most important are the ability to network and interact with peers and to share ideas, questions, points of view, successes and failures. The three Summer Schools on Innovative Approaches for the Identification of Antiviral Agents have been important events in the education programs of the next generation of scientists. Based on those successes, the fourth IAAASS will soon be under development for 2018.
